Investigating the Effects of Indirect Coculture of Human Mesenchymal Stem Cells on the Migration of Breast Cancer Cells: A Systematic Review and Meta-Analysis

Abstract

Purpose: Breast cancer is the most diagnosed cancer and the leading cause of cancer death in women globally, and mesenchymal stem cells have been widely implicated in tumour progression. This systematic review and meta-analysis seeks to identify and summarise existing literature on the effects of human mesenchymal stem cells (hMSCs) on the migration of breast cancer cells (BCCs) in vitro, to determine the direction of this relationship according to existing research and to identify the directions for future research. Methods: A systematic literature search was conducting using a collection of databases, using the following search terms: in vitro AND mesenchymal stem cells AND breast cancer. Only studies that investigated the effects of human, unmodified MSCs on the migration of human, unmodified BCCs in vitro were included. Standardised mean differences (SMDs) were calculated to determine pooled effect sizes. Results: This meta-analysis demonstrates that hMSCs (different sources combined) increase the migration of both MDA-MB-231 and MCF-7 cell lines in vitro (SMD = 1.84, P = .03 and SMD = 2.69, P < .00001, respectively). Importantly, the individual effects of hMSCs from different sources were also analysed and demonstrated that MSCs derived from human adipose tissue increase BCC migration (SMD = 1.34, P = .0002) and those derived from umbilical cord increased both MDA-MB-231 and MCF-7 migration (SMD = 3.93, P < .00001 and SMD = 3.01, P < .00001, respectively). Conclusions: To our knowledge, this is the first systematic review and meta-analysis investigating and summarising the effects of hMSCs from different sources on the migration of BCCs, in vitro.

Beneficios del ejercicio y/o actividad física en los cinco tipos de cáncer con mayor incidencia y mortalidad a nivel mundial: Una revisión narrativa

“…En 2020, hubo aproximadamente 2,3 millones de casos nuevos de cáncer de mama femenino en todo el mundo, correspondiente al 11,7 % de todos los casos nuevos de cáncer, asociados a 685.000 muertes (Müller et al, 2023). En 2020, el Reino Unido representó un 11,8% de todos los casos nuevos de cáncer de mama en ambos sexos y un 25,5% en casos nuevos en mujeres, donde, aunque los tratamientos para esta enfermedad han avanzado, la diseminación metastásica sigue siendo un mal y fatal pronóstico (Brown et al, 2023). Según los datos de Agencia Internacional para la Investigación del Cáncer (IARC, 2018) de 185 países, se dieron a conocer 2,3 millones (11,7%) de nuevos casos de cáncer de mamas con una tasa de mortalidad de 6,9% (Kashyap et al, 2022).…”